Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04943224 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

Study acronym: TRAM
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 15 words
    • Site details revised
    • Publications: details revised at 10 of 10 entries
  2. Primary and study completion dates: Mar 30, 2026 to Jun 30, 2027v7
  3. Re-verified, no change to tracked fieldsv6
  4. Study completion date: Jun 23, 2026 to Mar 30, 2026v5
  5. Eligibility criteria shortened, about 9 words
    • Study title shortened, about 10 words
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Eligibility criteria expanded, about 6 words
    • Study description shortened, about 2 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Prospective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of trametinib in juvenile patients with histiocytosis resistant to conventional therapy and without the BRAF gene mutation or after the failure of vemurafenib treatment.
Trial Details
NCT Number NCT04943224
Lead Sponsor Anna Raciborska
Collaborators: Maria Sklodowska-Curie National Research Institute of Oncology, Łukasiewicz Research Network, Wroclaw University of Environmental and Life Sciences
Conditions
(from sponsor)		 Histiocytosis
Related terms Histiocytosis, Histiocytosis, Langerhans-Cell
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov